ERIS - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 2.6
| Stock Code | ERIS | Market Cap | 20,071 Cr. | Current Price | 1,448 ₹ | High / Low | 1,888 ₹ |
| Stock P/E | 79.0 | Book Value | 231 ₹ | Dividend Yield | 0.51 % | ROCE | 11.1 % |
| ROE | 8.89 % | Face Value | 1.00 ₹ | DMA 50 | 1,379 ₹ | DMA 200 | 1,436 ₹ |
| Chg in FII Hold | -0.46 % | Chg in DII Hold | 0.04 % | PAT Qtr | -8.60 Cr. | PAT Prev Qtr | 17.0 Cr. |
| RSI | 61.8 | MACD | 13.7 | Volume | 1,09,041 | Avg Vol 1Wk | 58,287 |
| Low price | 1,200 ₹ | High price | 1,888 ₹ | PEG Ratio | -5.84 | Debt to equity | 0.66 |
| 52w Index | 36.1 % | Qtr Profit Var | -128 % | EPS | 17.6 ₹ | Industry PE | 32.5 |
📊 ERIS shows weak fundamentals for long-term investment at current valuations. The stock trades at a very high P/E (79.0 vs industry average 32.5), with poor ROE (8.89%) and ROCE (11.1%). EPS of 17.6 ₹ is modest, and the PEG ratio (-5.84) indicates negative growth prospects. Debt-to-equity at 0.66 is relatively high compared to peers. Dividend yield is low at 0.51%, offering limited income support. Recent quarterly losses further weaken the investment case.
💡 Ideal Entry Price Zone: Current price is 1,448 ₹, with DMA 50 at 1,379 ₹ and DMA 200 at 1,436 ₹. A safer entry zone would be between 1,200–1,300 ₹, closer to support levels, only if profitability improves.
📈 Exit Strategy: For existing holders, caution is advised. Investors should consider reducing exposure on rallies near 1,500–1,600 ₹. Long-term holding is only justified if ROE and ROCE improve significantly, EPS grows consistently, and debt levels reduce. Otherwise, a gradual exit is recommended.
🌟 Positive
- 📊 EPS remains positive (17.6 ₹), supporting valuation despite weak profitability.
- 📈 Strong trading volumes above weekly average, showing investor interest.
- 📊 DII holdings increased slightly (+0.04%), showing minor domestic support.
⚠️ Limitation
- 📉 Very high P/E (79.0) compared to industry average (32.5).
- 📊 Weak ROE (8.89%) and ROCE (11.1%), showing poor capital efficiency.
- 📉 PEG ratio (-5.84) indicates negative growth prospects.
📰 Company Negative News
- 📉 Quarterly PAT turned negative (-8.6 Cr vs 17 Cr previous quarter).
- 📊 Quarterly profit variation is sharply negative (-128%).
- 📉 FII holdings decreased (-0.46%).
📰 Company Positive News
- 📈 MACD at 13.7 indicates bullish momentum in short term.
- 📊 RSI at 61.8 shows moderate strength, not yet overbought.
🏭 Industry
- 📊 Industry PE is 32.5, much lower than company’s 79.0, highlighting overvaluation.
- 📈 Pharma sector growth supported by demand for specialty drugs and generics, though company-specific metrics lag peers.
✅ Conclusion
⚖️ ERIS is currently overvalued with weak profitability metrics and negative growth signals. It is not a strong candidate for long-term investment unless fundamentals improve significantly. Existing investors should consider exiting near 1,500–1,600 ₹ unless earnings recover and debt levels reduce.
For deeper insights, you could explore a peer comparison or a valuation analysis to refine entry and exit strategies.